Humacyte, Inc. (HUMA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 2 | 0 | 0 | 2 | 2 | 4 |
| Operating profit | $m | -107 | -111 | ||||||
| Net profit | $m | -67 | -26 | -12 | -111 | -149 | -41 | -97 | -65 |
| EPS reported | $ | -0.26 | -0.51 | ||||||
| Operating cashflow per share | $ | -0.66 | -0.42 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | -0.67 | -0.42 | ||||||
| Free cash flow | $m | -106 | -98 | ||||||
| Net debt | $m | -15 | -44 | ||||||
| Book value equity | $m | 3 | - | ||||||
| Book value per share | $ | 0.02 | 0.13 | ||||||
| Number of shares | m | 158.16 | 234.18 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 48.86 | 4.53 | ||||||
| P/S LTM | x | 74.54 | 71.62 | ||||||
| P/FCF LTM | x | -1.43 | -1.56 | ||||||
| EV/EBITDA LTM | x | -7.48 | -2.09 | ||||||
| EV/Sales LTM | x | 81.58 | 41.43 | ||||||
| Earnings Yield LTM | % | -26.88% | -68.30% | ||||||
| FCF Yield | % | -69.73% | -64.22% | ||||||
| Quality | |||||||||
| ROE | % | -1313.4% | -938.20% | ||||||
| ROIC | % | -1.07% | -89.17% | ||||||
| Operating margin | % | -52.72% | -52.41% | ||||||
| Gross margin | % | -7.36% | -6.67% | ||||||
| FCF/Sales | % | -5197.5% | -4599.7% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.63 | -1.47 | ||||||
| Net Debt/EBITDA | x | -0.65 | 0.17 | ||||||
| EBIT/Net interest | x | -9.55 | -10.80 | ||||||
| Net debt/market cap | % | +23.33% | +35.75% | ||||||
| Net debt/Equity | x | -4.84 | - | ||||||
| Gross debt/equity | x | 20.86 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free